ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based antithrombotic regimen following successful coronary stenting in atrial fibrillation patients

Reported from the European Society of Cardiology ESC Congress 2019 in Paris

• Question 1: How do you explain the difference in results between ENTRUST-AF-PCI and prior trials?
• Question 2: How would you explain the differences between the two meta-analyses presented during the session on Antithrombotic therapy in atrial fibrillation patients undergoing PCI?
• Question 3: Is a signal towards an excess of stent thrombosis with Aspirin withdrawal observed in several trials a statistical streak or is it a real clinical issue?